9 Meters Biopharma, Inc.
10
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
20.0%
2 terminated/withdrawn out of 10 trials
77.8%
-8.7% vs industry average
10%
1 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome.
Role: lead
Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms
Role: lead
Proof of Concept Study in Patients With Short Bowel Syndrome
Role: lead
Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease
Role: lead
A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease
Role: lead
Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease
Role: lead
Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease
Role: lead
Safety of Larazotide Acetate in Healthy Volunteers
Role: lead
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
Role: lead
Safety Study of Larazotide Acetate to Treat Celiac Disease.
Role: lead
All 10 trials loaded